Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Haoxu Ouyang, MD PhD, Ratesh Khillan, Nyein Htway Yu, MBBS, MD, Mohan Preet, MD

Blood (2019) 134 (Supplement_1): 4927.

https://doi.org/10.1182/blood-2019-132283

Published: 2019

Journal Articles

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Andrew Doyle, MBBS, BSc, FRPATH, Karen Breen, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia, Beverley J. Hunt, Gavin Ling, MBBS, BSc, FRCPath, Claire N Harrison, Professor, Natalia Curto Garcia, MD MBBS

Blood (2019) 134 (Supplement_1): 4183.

https://doi.org/10.1182/blood-2019-128170

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Blood (2019) 134 (Supplement_1): 4311.

https://doi.org/10.1182/blood-2019-130062

Published: 2019

Journal Articles

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Vishal K Gupta, MD, Romy Carmen Lawrence, MD BS, Sarah L. Khan, Rachel Strykowski, MD, Brittany Scarpato, MD, Robyn T. Cohen, MD MPH, John Mark Sloan, MD, Elizabeth S Klings, MD

Blood (2019) 134 (Supplement_1): 2272.

https://doi.org/10.1182/blood-2019-122113

Published: 2019

Journal Articles

Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes?

Ijele Adimora, Brendan E Dempsey, BA, Youdinghuan Chen, MS, Kari Rosenkranz, MD, Deborah L. Ornstein, MD, Monic R. Drescher, MD

Blood (2019) 134 (Supplement_1): 935.

https://doi.org/10.1182/blood-2019-125325

Published: 2019

Journal Articles

Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study

Siavash Piran, MDMSc, FRCPC, Marlene Robinson, BSN, RN, Erjona Kruja, BSc, Sam Schulman, MD PhD FRCPC

Blood (2018) 132 (Supplement 1): 5060.

https://doi.org/10.1182/blood-2018-99-116974

Published: 2018

Journal Articles

Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Jacki Day, BS, Allison Deal, MS, Yue Wang, PhD, Benyam Muluneh, PharmD, Daniel Crona, PharmD, PhD, Brandi Reeves, MD

Blood (2018) 132 (Supplement 1): 5468.

https://doi.org/10.1182/blood-2018-99-116713

Published: 2018

Journal Articles

Risk of Subsequent Thrombosis in Patients with Isolated Heparin-Induced Thrombocytopenia

Heather R Wolfe, MD, Yu-Min Shen, MD

Blood (2018) 132 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2018-99-117629

Published: 2018

Journal Articles

Poor Agreement between Commercially Available Anti-Cardiolipin and Anti-β2glycoprotein I IgG and IgM Solid Phase Assays Hampers Uniformity in the Classification of Antiphospholipid Syndrome Patients

Walid Chayouâ, MSc, Hilde Kelchtermans, PhD, Gary Moore, MD, Jean-Christophe Gris, MD PhD, Jacek Musial, MD PhD, Denis Wahl, MD PhD, Stéphane Zuily, MDPhD, Armando Tripodi, PhD, Pierre Fontana, MD PhD, Jasper A. Remijn, PhD, Bas De Laat, MD PhD, Katrien Devreese, MD PhD

Blood (2017) 130 (Supplement 1): 1059.

https://doi.org/10.1182/blood.V130.Suppl_1.1059.1059

Published: 2017

Journal Articles

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

Ami Chitalia, MD, David Swoboda, MD, Catherine Broome, MD

Blood (2016) 128 (22): 2603.

https://doi.org/10.1182/blood.V128.22.2603.2603

Published: 2016

Journal Articles

Hematological Parameters As Exclusion Criteria in Clinical Trials of Acute Coronary Syndrome

Ohad Oren, MD, Douglas F. Beach, MD

Blood (2016) 128 (22): 3593.

https://doi.org/10.1182/blood.V128.22.3593.3593

Published: 2016

Journal Articles

Direct Oral Anticoagulants in Patients with Cancer

Surbhi Shah, MBBS, Yvonne H Datta, MD, Faye Norby, MS, MPH, Alvaro Alonso, MD PhD MPH, FAHA

Blood (2016) 128 (22): 877.

https://doi.org/10.1182/blood.V128.22.877.877

Published: 2016

Journal Articles

Activated Immune Response in Ventricular Assist Device Implanted Patients Identified through a Platelet Activation Biomarker

Walter Jeske, PhD, Jeanine M. Walenga, PhD, Tania Torres, MS, BA, Vicki Escalante, BS, Jeffrey Schwartz, MD, Mamdouh Bakhos, MD

Blood (2016) 128 (22): 5001.

https://doi.org/10.1182/blood.V128.22.5001.5001

Published: 2016

Journal Articles

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Ross I Baker, MD, Grace Gilmore, Scott McGregor, BPharm

Blood (2016) 128 (22): 2626.

https://doi.org/10.1182/blood.V128.22.2626.2626

Published: 2016

Journal Articles

Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboembolism: A Retrospective Analysis

Jeremy A Ross, MD, Marilyn Miller, MSN-RN, FNP-C, Cristhiam M Rojas Hernandez, MD

Blood (2015) 126 (23): 1123.

https://doi.org/10.1182/blood.V126.23.1123.1123

Published: 2015

Journal Articles

A Comprehensive Review of IVC Filters in a Community Tertiary Center

Benjamin Parsons, DO, Peter Polewski, MD, Angela Smith, MA, Kurt Ziegelbein, MD, Andrew Horstman, PA-C, Ezana Azene, MD PhD, Shannon Brozak, PA-C, Mason Fisher, MD, Paul Escher

Blood (2015) 126 (23): 1136.

https://doi.org/10.1182/blood.V126.23.1136.1136

Published: 2015

Journal Articles

Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study

John K Abdou, MPharm, Jignesh P Patel, PhD, Bipin Vadher, MD, Alison Brown, BPharm, Lara N Roberts, MD, Raj K Patel, MD, Roopen Arya, PhD, Vivian Auyeung, PhD

Blood (2015) 126 (23): 2331.

https://doi.org/10.1182/blood.V126.23.2331.2331

Published: 2015

Journal Articles

Retrospective Cohort of Unprovoked Venous Thromboembolism Patients: What Proportion Have Potent Thrombophilias Necessitating Indefinite Anticoagulants?

Junghyun Park, BSc, Marc Rodger, MD MSc

Blood (2015) 126 (23): 2318.

https://doi.org/10.1182/blood.V126.23.2318.2318

Published: 2015

NARROW

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

The Real World Experience Regarding the Safety of Rivaroxaban and Apixaban in Venous Thromboembolism Patients with High Bleeding Risk

Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease

Perioperative Bridging of Anticoagulation - Does Protocol Adherence Improve Outcomes?

Reasons for Switching from Warfarin to a Direct Oral Anticoagulant: A Retrospective Study

Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Risk of Subsequent Thrombosis in Patients with Isolated Heparin-Induced Thrombocytopenia

Poor Agreement between Commercially Available Anti-Cardiolipin and Anti-β2glycoprotein I IgG and IgM Solid Phase Assays Hampers Uniformity in the Classification of Antiphospholipid Syndrome Patients

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

Hematological Parameters As Exclusion Criteria in Clinical Trials of Acute Coronary Syndrome

Direct Oral Anticoagulants in Patients with Cancer

Activated Immune Response in Ventricular Assist Device Implanted Patients Identified through a Platelet Activation Biomarker

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Comparative Effectiveness and Safety of Direct Oral Anticoagulants (DOAC) Versus Conventional Anticoagulation for the Treatment of Cancer-Related Venous Thromboembolism: A Retrospective Analysis

A Comprehensive Review of IVC Filters in a Community Tertiary Center

Patients Prescribed Warfarin with Poor Time in Therapeutic Range (TTR) Have Different Beliefs about Their Illness and Anticoagulation Therapy Compared to Those with a Good TTR - Early Results from the Switching Study

Retrospective Cohort of Unprovoked Venous Thromboembolism Patients: What Proportion Have Potent Thrombophilias Necessitating Indefinite Anticoagulants?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only